Bristol Myers Squibb (CELG-RI) Stock: Why It's Down Today
Updated Oct 19, 2026, 4:00 PM ET · closing price
- Closed at $0.11, -10.01% vs the prior close of $0.12.
- Volume 2.03K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CELG-RI slides 10.0% to $0.11. Closed at $0.11, -10.01% vs the prior close of $0.12. Day range $0.11–$0.11, opened at $0.12.
CELG-RI daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — CELG-RI slides 10.0% to $0.11
- Closed at $0.11, -10.01% vs the prior close of $0.12. Day range $0.11–$0.11, opened at $0.12.
- Volume was 2.03K shares, 1.0x its 50-day average of 2.03K.
- 52-week range $0.11–$0.12; today's close sits at 10% of that range, 10.0% below the 52-week high.
CELG-RI bull case vs bear case (from the data)
- Latest fiscal-year net income: profit of $7.05B.
- Annual revenue fell 0.2% in the latest fiscal year (SEC XBRL).
- Insider selling outweighs buying: 16 sales vs 0 open-market buys among the 16 most recent reported insider trades (Form 4, last 12 months).
- High volatility: average daily move of 10.0% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
CELG-RI latest news & SEC filings
Every SEC filing by or about CELG-RI in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gallman Cari converted options/RSUs into 4,559 shares on Oct 2, 2026; now holds 18,208
- Gallman Cari had withheld for taxes 2,332 shares at $61.15 (≈$142.60K) on Oct 2, 2026; now holds 15,876
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 30, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $12.97B (prior year $12.27B) (+5.7% vs Jun 30, 2025)
- Net income: $3.32B (prior year $1.31B) (+153.2% vs Jun 30, 2025)
- Diluted EPS: $1.62 (prior year $0.64) (+153.1% vs Jun 30, 2025)
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade CELG-RI
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Feb 5, 2026, Oct 30, 2025. Based on that rhythm, the next report is likely around Oct 29, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 10.01% (largest 10.0%). That is a volatile stock.
- Liquidity: about 2.03K shares (≈$219) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.11 vs a range of $0.11–$0.12 (10% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 16 sales; latest: Cristian Massacesi sold 6,249 shares on Sep 9, 2026.
- Latest filings: 10-Q Jul 30, 2026; 8-K Jul 30, 2026; 8-K May 8, 2026.
- Share count: 2.04B shares outstanding (Jul 22, 2026), +0.4% vs a year earlier.
- Listing: NYSE · industry: Pharmaceutical Preparations.
CELG-RI market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 0.12 | 0.11 | 0.11 | 0.11 | 2.03K |
| Oct 16, 2026 | 0.10 | 0.12 | 0.11 | 0.12 | 2.03K |
About Bristol Myers Squibb
Bristol Myers Squibb (CELG-RI) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in PRINCETON, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 14272.
CELG-RI board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Peter J Arduini | Director | Jul 2, 2026 |
| Christopher S. Boerner | Chief Executive Officer | Mar 12, 2026 |
| Deepak Bhatt | Director | Feb 3, 2026 |
| Julia A Haller | Director | Jun 16, 2026 |
| Medina Manuel Hidalgo | Director | Feb 3, 2026 |
| Michael R. Mcmullen | Director | Jul 2, 2026 |
| Paula A Price | Director | Feb 3, 2026 |
| Derica W Rice | Director | Jul 2, 2026 |
| Theodore R. Ii Samuels | Director | Jul 2, 2026 |
| Karen H Vousden | Director | Feb 3, 2026 |
| Phyllis R Yale | Director | Jul 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christopher S. Boerner | Chief Executive Officer | Mar 12, 2026 |
| David V Elkins | EVP, Chief Financial Officer | Apr 2, 2026 |
| Cari Gallman | EVP, General Counsel | Aug 4, 2026 |
| Benjamin Hickey | President, RayzeBio Org. | Mar 12, 2026 |
| Lynelle Hoch | President, Cell Therapy Org. | Mar 12, 2026 |
| Phil M Holzer | SVP and Controller | Aug 26, 2026 |
| Adam Lenkowsky | EVP, Chief Commercial Officer | May 5, 2026 |
| Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | Sep 10, 2026 |
| Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | Mar 12, 2026 |
| Robert M Plenge | EVP, Chief Research Officer | Mar 12, 2026 |
| Ahn Amanda Poole | EVP, Chief People Officer | Mar 12, 2026 |
| Karin Shanahan | EVP, Chief Supply Chain & Ops | Apr 2, 2026 |
| Hiroshi Chris Shibutani | EVP, Chief Strategy Officer | Mar 12, 2026 |
| Bartie Wendy Short | EVP, Corporate Affairs | Sep 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 9, 2026 | Cristian Massacesi | Sale | 6,249 | $64.57 |
| Sep 9, 2026 | Cristian Massacesi | Sale | 6,249 | $64.57 |
| Sep 9, 2026 | Cristian Massacesi | Sale | 6,249 | $64.57 |
| Sep 9, 2026 | Cristian Massacesi | Sale | 6,249 | $64.57 |
| Aug 25, 2026 | Phil M Holzer | Sale | 500 | $67.50 |
| Aug 25, 2026 | Phil M Holzer | Sale | 500 | $67.50 |
| Aug 25, 2026 | Phil M Holzer | Sale | 500 | $67.50 |
| Aug 25, 2026 | Phil M Holzer | Sale | 500 | $67.50 |
| Apr 1, 2026 | David V Elkins | Sale | 25,519 | $61.60 |
| Apr 1, 2026 | David V Elkins | Sale | 4,481 | $62.05 |
| Apr 1, 2026 | David V Elkins | Sale | 25,519 | $61.60 |
| Apr 1, 2026 | David V Elkins | Sale | 4,481 | $62.05 |
| Apr 1, 2026 | David V Elkins | Sale | 25,519 | $61.60 |
| Apr 1, 2026 | David V Elkins | Sale | 4,481 | $62.05 |
| Apr 1, 2026 | David V Elkins | Sale | 25,519 | $61.60 |
CELG-RI financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $48.19B | $7.05B | 3.46 | $14.16B |
| Dec 31, 2024 | $48.30B | $-8.95B | -4.41 | $15.19B |
| Dec 31, 2023 | $45.01B | $8.03B | 3.86 | $13.86B |
| Dec 31, 2022 | $46.16B | $6.33B | 2.95 | $13.07B |
| Dec 31, 2021 | $46.38B | $6.99B | 3.12 | $16.21B |
Latest balance sheet: total assets $87.63B, total liabilities $65.31B, cash $8.72B (as of Jun 30, 2026).
CELG-RI earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | — |
| Apr 30, 2026 | 8-K Item 2.02 (results) | — |
| Feb 5, 2026 | 8-K Item 2.02 (results) | — |
| Oct 30, 2025 | 8-K Item 2.02 (results) | — |
| Jul 31, 2025 | 8-K Item 2.02 (results) | — |
| Apr 24, 2025 | 8-K Item 2.02 (results) | — |
| Feb 6, 2025 | 8-K Item 2.02 (results) | — |
| Oct 31, 2024 | 8-K Item 2.02 (results) | — |
| Jul 26, 2024 | 8-K Item 2.02 (results) | — |
| Apr 25, 2024 | 8-K Item 2.02 (results) | — |
| Feb 2, 2024 | 8-K Item 2.02 (results) | — |
| Oct 26, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)United Therapeutics (UTHR)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Tesla (TSLA)Space Exploration Technologies (SPCX)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on CELG-RI
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 19, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.